ClinVar

Description

The MSH2 c.2680dupA variant is predicted to result in a frameshift and premature protein termination (p.Met894Asnfs*5). This variant has been reported in at least five individuals with Lynch syndrome cancers and an additional individual undergoing Lynch syndrome genetic testing (Table 6. Casey et al. 2005. PubMed ID: 15713769; Table S1, Carter et al. 2018. PubMed ID: 30322717; Table 1, Lagerstedt-Robinson et al. 2016. PubMed ID: 27601186; Table A2, Espenschied et al. 2017. PubMed ID: 28514183; Sup. Material 2, Svensson et al. 2022. PubMed ID: 35430768; Case 1, Bujassoum et al. 2018. J Cancer Sci Ther. 10:9. DOI: 10.4172/1948-5956.1000550). It has also been reported in a mismatch repair deficient Lynch syndrome tumor specimen (Table S2, Henriksson et al. 2019. PubMed ID: 30251116). This variant is reported in 3 of ~251,000 alleles in gnomAD (https://gnomad.broadinstitute.org/variant/2-47709960-C-CA?dataset=gnomad_r2_1). It has conflicting classifications listed in ClinVar ranging from uncertain to pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/229809/). This variant resides in the final exon of this gene, and it is unclear if the resulting mRNA would undergo nonsense-mediated decay. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.